Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q2VN
|
|||
| Former ID |
DIB018219
|
|||
| Drug Name |
[3H]4NMPB
|
|||
| Synonyms |
[3H](1-methyl-4-piperidyl) 2-hydroxy-2,2-diphenyl-acetate; [3H]1-Methyl-4-piperidyl diphenylglycolate; [3H]enpiperate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H23NO3
|
|||
| Canonical SMILES |
CN1CCC(CC1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O
|
|||
| InChI |
1S/C20H23NO3/c1-21-14-12-18(13-15-21)24-19(22)20(23,16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18,23H,12-15H2,1H3
|
|||
| InChIKey |
UGYPGJCVNPPUPE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 3608-67-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Muscarinic acetylcholine receptor (CHRM) | Target Info | Antagonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Cholinergic synapse | ||||
| Regulation of actin cytoskeleton | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Muscarinic acetylcholine receptors | |||
| Acetylcholine regulates insulin secretion | ||||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| Regulation of Actin Cytoskeleton | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Secretion of Hydrochloric Acid in Parietal Cells | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 352). | |||
| REF 2 | Cloned M1 muscarinic receptors mediate both adenylate cyclase inhibition and phosphoinositide turnover. EMBO J. 1988 Oct;7(10):3031-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.